ReviewMolecular psychiatry2007
Rationale for a trial of immunosuppressive therapy in acute schizophrenia.
Review in Molecular psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 51 citations in OpenAlex.
- Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.Psychopharmacology · 2014Trial
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009Trial
- NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?Trends in neurosciences · 2016Review
- Article
- Inflammation and the two-hit hypothesis of schizophrenia.Neuroscience and biobehavioral reviews · 2014Review
- Article
- Myasthenia gravis, schizophrenia, and colorectal cancer in a patient: long-term follow-up with medication complexity.Psychiatry investigation · 2013Article
- Immunization with DAT fragments is associated with long-term striatal impairment, hyperactivity and reduced cognitive flexibility in mice.Behavioral and brain functions : BBF · 2012Article
- Diagnosis of infectious or inflammatory psychosyndromes.The open neurology journal · 2012Article
- Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer.Molecular psychiatry · 2009Review
- Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia.European archives of psychiatry and clinical neuroscience · 2008Article
- Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice.Psychopharmacology · 2008Article
- Classification in psychiatry: Does it deliver in schizophrenia and depression?International journal of mental health systems · 2007Article
- Allelic frequencies of 3' Ig heavy chain locus enhancer HS1,2-A associated with Ig levels in patients with schizophrenia.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a debilitating, costly, socially disruptive, life-threatening disease in which available treatments are largely palliative and empirical, and produce significant short- and long-term side effects. Therefore, a strong case can made for exploring alternative treatments with a rational basis for use in this disease. Considerable evidence indicates that autoimmune processes may be involved in some forms of schizophrenia, including altered risk of certain autoimmune diseases in patients and their relatives, shared epidemiological features, and apparent involvement of genes known to influence the immune response repertoire. Attempts to provide direct evidence for autoimmune processes have proven elusive, possibly due to the technical difficulty inherent in accessing autoantibodies with high affinity for brain cell-surface receptors. In view of this impasse, we argue for a well-designed trial in schizophrenia of immunosuppressive therapy, which is now the mainstay of therapy for many autoimmune diseases. Analysis of disease states in which immunosuppression has been effectively used over many decades provides guidelines necessary for a meaningful trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.